Stocktoria
INCYTE CORP INCY
INCYTE CORP (INCY) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $5.1B at a 25.0% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-08-04 | Mizuho | Outperform (main) |
| 2026-08-03 | Leerink Partners | Outperform (main) |
| 2026-08-03 | HC Wainwright & Co. | Buy (reit) |
| 2026-07-29 | RBC Capital | Sector Perform (main) |
| 2026-07-29 | Guggenheim | Buy (main) |
| 2026-07-29 | BMO Capital | Market Perform (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.504 |
| Retained earnings / assets | 0.031 |
| EBIT / assets | 0.218 |
| Equity / liabilities | 2.886 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| INCY | INCYTE CORP | 6/9 | 7.9 | 17.7 | +21.2% |
| CRL | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | 4/9 | 1.81 | — | -0.9% |
| MEDP | Medpace Holdings, Inc. | 6/9 | 0.2 | 33.4 | +20% |
| ICLR | ICON PLC | 6/9 | 2.1 | 56.7 | +0.8% |
| NRC | NRC HEALTH | 3/9 | 0.03 | — | -4% |
| OABI | OmniAb, Inc. | 1/9 | 6 | — | -29.3% |
| BIAF | bioAffinity Technologies, Inc. | 3/9 | — | — | — |
About INCYTE CORP
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
FAQ
Is INCY financially healthy?
INCYTE CORP's Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does INCY pay a dividend?
No, INCYTE CORP does not currently pay a dividend.
How profitable is INCY?
In FY2025, INCYTE CORP had a net margin of 25.0% and a return on equity of 24.9%.
Is INCY overvalued or undervalued?
INCYTE CORP trades at about 18.8× trailing earnings — below its 10-year norm (10-year range 15.6×–2352.0×, median 56.0×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for INCY?
The average Wall-Street price target for INCYTE CORP is $124.96, about 3.5% above the recent price, from 23 analysts (consensus: buy).
Is INCY a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on INCYTE CORP: a Piotroski F-score of 6/9, an Altman Z″ in the safe zone, a P/E of about 17.7×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.